Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pradip De

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
American Journal of Translational Research|December 23, 2015
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsNandini Dey, Pradip De, Leyland-Jones Brian
American Journal of Cancer Research|January 29, 2015
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancersNandini Dey, Brian Leyland-Jones, Pradip De
American Journal of Cancer Research|May 6, 2020
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapiesJordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, et al.
Cancers|March 25, 2022
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated ResistancePradip De, Jennifer Aske, Raed Sulaiman, et al.
International Journal of Molecular Sciences|June 24, 2022
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment OpportunityNischal Koirala, Nandini Dey, Jennifer Aske, et al.
American Journal of Cancer Research|January 22, 2019
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approachAnita Gul, Brain Leyland-Jones, Nandini Dey, et al.
American Journal of Translational Research|June 12, 2015
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTKNandini Dey, Casey Williams, Brain Leyland-Jones, et al.
Oncotarget|July 13, 2014
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many handsPradip De, Jennifer Carlson, Brian Leyland-Jones, et al.
Cancer Treatment Reviews|April 4, 2017
Mutation matters in precision medicine: A future to believe inNandini Dey, Casey Williams, Brian Leyland-Jones, et al.
Cancer Treatment Reviews|January 29, 2013
Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hopePradip De, Keith Miskimins, Nandini Dey, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
American Journal of Translational Research|December 23, 2015
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsNandini Dey, Pradip De, Leyland-Jones Brian
American Journal of Cancer Research|January 29, 2015
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancersNandini Dey, Brian Leyland-Jones, Pradip De
American Journal of Cancer Research|May 6, 2020
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapiesJordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, et al.
Cancers|March 25, 2022
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated ResistancePradip De, Jennifer Aske, Raed Sulaiman, et al.
International Journal of Molecular Sciences|June 24, 2022
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment OpportunityNischal Koirala, Nandini Dey, Jennifer Aske, et al.
American Journal of Cancer Research|January 22, 2019
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approachAnita Gul, Brain Leyland-Jones, Nandini Dey, et al.
American Journal of Translational Research|June 12, 2015
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTKNandini Dey, Casey Williams, Brain Leyland-Jones, et al.
Oncotarget|July 13, 2014
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many handsPradip De, Jennifer Carlson, Brian Leyland-Jones, et al.
Cancer Treatment Reviews|April 4, 2017
Mutation matters in precision medicine: A future to believe inNandini Dey, Casey Williams, Brian Leyland-Jones, et al.
Cancer Treatment Reviews|January 29, 2013
Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hopePradip De, Keith Miskimins, Nandini Dey, et al.
Pageof 7